Open Access Highly Accessed Research article

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides*, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos N Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos N Syrigos and George Fountzilas

BMC Cancer 2012, 12:271  doi:10.1186/1471-2407-12-271

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Post a comment